Editor’s note: On International Clinical Trials day, Cynthia Verst, the president of Clinical Operations at Durham-based Quintiles (NYSE: Q), writes that the use of secondary data earlier in the research process can lead to “smarter, faster and more cost-sensitive clinical trials.”
DURHAM, N.C. – Today is International Clinical Trials Day, a day in which we celebrate the great achievements of clinical researchers who bring life-saving treatments to fruition, and acknowledge the work we are doing today to make the trials of the future even more effective. For many of us, the key to that efficiency is speed. We all want to deliver smarter, faster and more cost-sensitive clinical trials so that we can get treatments to patients sooner and at less cost. By integrating evidence earlier in the clinical research process, we can help make this vision a reality.
Design with the end in mind
Leveraging secondary data, including electronic health records (EHR) or electronic medical records (EMR), claims data, prescription data and other data sources during the planning stage of a trial enables sponsors to optimize protocol designs and to reduce the risk against unnecessary, downstream protocol modifications. We consider this a “defensive design” approach because it provides study leaders with insight into the patient’s disease journey and treatment pathways, and they can use this data to make practical, pragmatic decisions about protocol design and execution. This approach can also shed light on issues that can negatively impact the trial downstream, such as overly restrictive inclusion/exclusion criteria that will impede patient enrollment and extend timelines.
Pulling in evidence-based data collection earlier in the trial process also provides “offensive design” benefits. While most trial leaders understand the regulatory requirements needed to achieve product approval, they may not have that level of clarity around the expectations of payers, Health Technology Assessment (HTA) groups, and the providers who may ultimately prescribe these drugs. Too often, trial leaders don’t even consider the myriad needs of these stakeholders until late phase research, when it becomes far more costly and time consuming to gather the evidence needed to support pricing expectations and convince payers and providers of the real-world value of their treatment.
When trial leaders research the expectations of all stakeholders from the outset of the trial, they ask better questions, which enables them to gather more meaningful evidence and identify the patient important outcomes and related endpoints that stakeholders will need to make informed decisions about the value of the product.
Importantly, earlier and more proactive comprehensive evidence planning in clinical development can provide more robust pre-market scientific awareness, well before product launch.
Data-driven site identification and patient recruitment
In addition to optimizing protocol development, secondary data can be leveraged to accelerate site identification and patient enrollment.
By harnessing the power of secondary data insights and associated analytical tools, we can obtain a more accurate picture of how many patients an investigator can expect to recruit into a specific trial, assuming the exact inclusion and exclusion criterion of the protocol. Simply put, robust secondary data (i.e., electronic health records, claims data, prescription records, etc.) and analytical tools can help point us to the right investigational sites that have the right patient populations for a specific protocol.
The ability to leverage secondary data will help to accelerate patient enrollment. In fact, poor patient recruitment is one of the most common reasons for clinical trial failure.
The trial of the future has to be designed and implemented smarter, faster and more cost efficiently if we are going to meet the dynamic needs of patients and sponsors. The data exists to make that possible, now we just need to change the way we think about trial planning so we can make the most of these valuable tools.
(C) Quintiles
Bio: Cynthia Verst, PharmD, MS
- President, Clinical Operations, Quintiles
Cynthia L. Verst is president of Clinical Operations at Quintiles, a position she was appointed to in 2015. In this capacity, her responsibilities span the clinical development spectrum across the Quintiles organization. Previously, she served as president of Real-World & Late Phase Research at Quintiles.
Verst has more than 20 years of biopharmaceutical industry experience and a proven track record of operational leadership and innovation. Prior to joining Quintiles, she served as senior vice president, Global Late Phase Research, for OptumInsight (a division of UnitedHealth Group, formerly i3), where she and her team successfully established a new global Late Phase Research Business Unit. Previously, Verst and her team established and led Kendle’s global Late Phase Business Unit. She began her career in biopharma at Procter & Gamble Pharmaceuticals as Section Head in its North American Medical and Technical Affairs group, successfully leading the Phase IIIB/IV research requirements of marketed products.
Verst was named one of the top women in biotech in 2014 by FierceBiotech, an annual award that spotlights an elite list of 15 women leaders in the life sciences, academia and regulatory roles.
Verst holds a Pharm.D. and bachelor of science degree in Pharmacy from the University of Cincinnati, a master of science in Structural and Cellular Biology from the University of Illinois, and a bachelor of science degree in Biology and Chemistry from Northern Kentucky University.
Source: Quintiles
